Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies
Sign Up to like & getrecommendations! Published in 2018 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2017.5332
Abstract: Importance Longitudinal circulating tumor DNA (ctDNA) has been shown to predict response and survival in patients with metastatic melanoma treated with anti–programmed cell death 1 (PD-1) antibodies. Pseudoprogression, defined as radiologic finding of disease progression… read more here.
Keywords: ctdna; response; ctdna profile; disease ... See more keywords
Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Medicine"
DOI: 10.1002/cam4.2797
Abstract: PD(L)1 antibodies (anti‐PD(L)‐1) have been a major breakthrough in several types of cancer. Novel patterns of response and progression have been described with anti‐PD(L)‐1. We aimed at characterizing pseudoprogression (PSPD) among patients with various solid… read more here.
Keywords: tumor types; patients treated; evidence pseudoprogression; pseudoprogression ... See more keywords
Early pseudoprogression and progression lesions in glioblastoma patients are both metabolically heterogeneous
Sign Up to like & getrecommendations! Published in 2024 at "NMR in Biomedicine"
DOI: 10.1002/nbm.5095
Abstract: The standard treatment in glioblastoma includes maximal safe resection followed by concomitant radiotherapy plus chemotherapy and adjuvant temozolomide. The first follow‐up study to evaluate treatment response is performed 1 month after concomitant treatment, when contrast‐enhancing regions… read more here.
Keywords: treatment; contrast enhancing; enhancing regions; metabolically heterogeneous ... See more keywords
Pushing the limits of immune-related response: a case of “extreme pseudoprogression”
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Immunology, Immunotherapy"
DOI: 10.1007/s00262-018-2167-3
Abstract: The advent of immune checkpoint targeted immunotherapy has seen a spectrum of immune-related phenomena in both tumor responses and toxicities. We describe a case of pseudoprogression that pushes the limits of immune-related response criteria and… read more here.
Keywords: limits immune; immune related; case; related response ... See more keywords
DCE-MRI perfusion predicts pseudoprogression in metastatic melanoma treated with immunotherapy
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Neuro-Oncology"
DOI: 10.1007/s11060-019-03379-6
Abstract: Purpose It can be challenging to differentiate pseudoprogression from progression. We assessed the ability of dynamic contrast enhanced T1 MRI (DCE-MRI) perfusion to identify pseudoprogression in melanoma brain metastases. Methods Patients with melanoma brain metastases… read more here.
Keywords: pseudoprogression; dce mri; progression; mri perfusion ... See more keywords
MR perfusion characteristics of pseudoprogression in brain tumors treated with immunotherapy – a comparative study with chemo-radiation induced pseudoprogression and radiation necrosis
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Neuro-Oncology"
DOI: 10.1007/s11060-024-04910-0
Abstract: Pseudoprogression is an atypical imaging pattern of response to immunotherapy in patients with brain tumors. MR perfusion studies in this field are limited. The purpose of our study is to compare the perfusion features between… read more here.
Keywords: radiation; brain tumors; perfusion; pseudoprogression ... See more keywords
Pseudoprogression after glioma therapy: an update
Sign Up to like & getrecommendations! Published in 2017 at "Expert Review of Neurotherapeutics"
DOI: 10.1080/14737175.2017.1375405
Abstract: ABSTRACT Introduction: Initial diagnostics and follow-up of gliomas is usually based on contrast-enhanced MRI. However, the capacity of standard MRI to differentiate neoplastic tissue from posttherapeutic effects such as pseudoprogression is limited. Advanced neuroimaging methods… read more here.
Keywords: pseudoprogression; glioma therapy; pwi; pseudoprogression glioma ... See more keywords
RADT-23. MOLECULAR PROFILING OF GLIOMAS: INSIGHTS INTO RADIONECROSIS AND PSEUDOPROGRESSION THROUGH NEXT-GENERATION SEQUENCING
Sign Up to like & getrecommendations! Published in 2024 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noae165.0307
Abstract: Gliomas, the most common primary tumors of the CNS, presenting diagnostic and therapeutic challenges due to their heterogeneity. Next-generation sequencing (NGS) enhances diagnostic precision by identifying genetic alterations, guiding accurate diagnosis and personalized treatment strategies.… read more here.
Keywords: treatment; next generation; pseudoprogression; radionecrosis ... See more keywords
EFFECTIVENESS OF BEVACIZUMAB TO MANAGE SYMPTOMATIC STEROID REFRACTORY PSEUDOPROGRESSION OCCURRING DURING OR EARLY FOLLOWING RADIATION THERAPY FOR GLIOBLASTOMA
Sign Up to like & getrecommendations! Published in 2025 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaf185.108
Abstract: Approximately 15% of patients with glioblastoma (GBM) managed with Stupp Protocol(Stupp60Gy), experience symptomatic steroid-refractory mass effects from pseudoprogression resulting in significant morbidity. Beva- cizumab (BEV) potentially produces a clinical response allowing corticosteroid minimisation and completion… read more here.
Keywords: cohort; refractory; symptomatic steroid; bev ... See more keywords
Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression
Sign Up to like & getrecommendations! Published in 2019 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noy160
Abstract: BACKGROUND Noninvasively differentiating therapy-induced pseudoprogression from recurrent disease in patients with glioblastoma is prospectively difficult due to the current lack of a biologically specific imaging metric. Ferumoxytol iron oxide nanoparticle MRI contrast characterizes innate immunity… read more here.
Keywords: ferumoxytol gadolinium; contrast; pseudoprogression; oncology ... See more keywords
Pseudoprogression in a patient with metastatic melanoma treated with PD-1 and LAG-3 inhibition.
Sign Up to like & getrecommendations! Published in 2024 at "Melanoma research"
DOI: 10.1097/cmr.0000000000000974
Abstract: Pseudoprogression encapsulates a process of temporary radiographic growth followed by subsequent regression of metastatic melanoma lesions in response to immune checkpoint blockade (ICB), such as the combination of anti-programmed cell death protein 1 (PD-1) and… read more here.
Keywords: pseudoprogression patient; metastatic melanoma; patient metastatic; pseudoprogression ... See more keywords